Intellectus Partners LLC Raises Position in Novo Nordisk A/S $NVO

Intellectus Partners LLC grew its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 24.6% during the second quarter, according to the company in its most recent disclosure with the SEC. The fund owned 10,881 shares of the company’s stock after buying an additional 2,149 shares during the quarter. Intellectus Partners LLC’s holdings in Novo Nordisk A/S were worth $751,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Stone House Investment Management LLC bought a new position in shares of Novo Nordisk A/S during the first quarter valued at approximately $30,000. Disciplina Capital Management LLC grew its stake in shares of Novo Nordisk A/S by 162.3% during the first quarter. Disciplina Capital Management LLC now owns 480 shares of the company’s stock valued at $33,000 after buying an additional 297 shares during the last quarter. Dagco Inc. bought a new position in shares of Novo Nordisk A/S during the first quarter valued at approximately $35,000. Mid American Wealth Advisory Group Inc. bought a new position in shares of Novo Nordisk A/S during the second quarter valued at approximately $37,000. Finally, State of Wyoming bought a new position in shares of Novo Nordisk A/S during the first quarter valued at approximately $38,000. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Down 0.7%

Novo Nordisk A/S stock opened at $49.11 on Tuesday. The business has a fifty day moving average of $56.03 and a two-hundred day moving average of $61.85. The company has a quick ratio of 0.56, a current ratio of 0.78 and a debt-to-equity ratio of 0.52. The firm has a market cap of $219.26 billion, a P/E ratio of 13.49, a P/E/G ratio of 2.33 and a beta of 0.68. Novo Nordisk A/S has a twelve month low of $45.05 and a twelve month high of $112.52.

Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Wednesday, August 6th. The company reported $0.97 earnings per share for the quarter, topping analysts’ consensus estimates of $0.93 by $0.04. The company had revenue of $11.69 billion during the quarter, compared to analyst estimates of $77.51 billion. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%. On average, analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The business also recently announced a semi-annual dividend, which was paid on Tuesday, August 26th. Shareholders of record on Monday, August 18th were issued a dividend of $0.4119 per share. The ex-dividend date was Monday, August 18th. This represents a yield of 240.0%. Novo Nordisk A/S’s dividend payout ratio is currently 22.53%.

Analyst Ratings Changes

NVO has been the topic of a number of analyst reports. Wall Street Zen cut Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Saturday, August 2nd. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Novo Nordisk A/S in a research note on Tuesday, October 14th. BNP Paribas Exane raised Novo Nordisk A/S from an “underperform” rating to a “neutral” rating and set a $54.00 target price on the stock in a research note on Wednesday, August 13th. HSBC set a $70.00 price objective on Novo Nordisk A/S in a research note on Wednesday, October 1st. Finally, Jefferies Financial Group initiated coverage on Novo Nordisk A/S in a research note on Monday, October 27th. They issued an “underperform” rating on the stock. Two investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, ten have given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $76.00.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.